Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 6, Issue 3, Pages 241-242

Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases

1Service de Rhumatologie, CHRU Dupuytren, 2 rue M. Luther King, Limoges 87042, France
2Laboratoire d'Hématologie Expérimentale, Faculté de Médecine, 2 rue Dr. Marcland, Limoges 87025, France

Copyright © 1997 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


PAF is a potent inflammatory compound known to stimulate the release of various cytokines involved in rheumatic diseases. Elevated blood PAF levels are reported in these patients. We report that serum PAF acetylhydrolase activity (AHA) levels are decreased in patients with rheumatoid arthritis or osteoarthritis as compared to healthy controls. Serum and synovial fluid AHA levels were correlated in these patients. The present study suggests the potential role of AHA in controling systemic and/or local PAF levels in patients with rheumatic diseases.